Flurpiridaz F18

DRUG2 trials

Sponsors

Lantheus Medical Imaging

Conditions

Coronary Artery Disease

Phase 3

A Phase 3 Multi-center Study to Assess PET Imaging of Flurpiridaz F 18 Injection in Patients With CAD.

CompletedNCT01347710

Lantheus Medical ImagingCoronary Artery Disease

Start: 2011-06-30End: 2013-09-30Updated: 2020-11-24

Open Label Study to Access Flurpiridaz F18 in PET MPI Verses SPECT MPI

WithdrawnNCT01681524

Lantheus Medical ImagingCoronary Artery Disease

Start: 2012-11-30End: 2014-05-31Updated: 2013-05-30

Related Papers

Dynamic frame-by-frame motion correction for <sup>18</sup>F-flurpiridaz PET-MPI using convolution neural network.

2025-11-20

Utility of <sup>18</sup>F-Flurpiridaz PET Relative Flow Reserve in Differentiating Obstructive From Nonobstructive Coronary Artery Disease.

2025-10-091 citations

General Purpose Deep Learning Attenuation Correction Improves Diagnostic Accuracy of SPECT MPI: A Multicenter Study.

2025-08-082 citations

Subendocardial quantification enhances coronary artery disease detection in <sup>18</sup>F-flurpiridaz PET.

2025-03-055 citations

Automatic motion correction for myocardial blood flow estimation improves diagnostic performance for coronary artery disease in <sup>18</sup>F-flurpiridaz positron emission tomography-myocardial perfusion imaging.

2024-11-066 citations

Automated quantitation of 18F-flurpiridaz PET MPI and its diagnostic performance of coronary artery disease

European Heart Journal - Cardiovascular Imaging2024-06-271 citations

Integrated myocardial flow reserve (iMFR) assessment: optimized PET blood flow quantification for diagnosis of coronary artery disease.

2023-10-0910 citations

Multi-center, multi-vendor validation of deep learning-based attenuation correction in SPECT MPI: data from the international flurpiridaz-301 trial.

2022-11-1912 citations

Improved myocardial blood flow estimation with residual activity correction and motion correction in <sup>18</sup>F-flurpiridaz PET myocardial perfusion imaging.

2021-12-3028 citations

Phase-III Clinical Trial of Fluorine-18 Flurpiridaz Positron Emission Tomography for Evaluation of Coronary Artery Disease.

2020-07-01101 citations

Added value of myocardial blood flow using <sup>18</sup>F-flurpiridaz PET to diagnose coronary artery disease: The flurpiridaz 301 trial.

2020-01-3044 citations